Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
